2
Announcements
Trials
Browse
Landscape
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Observational
2
Sponsor
Conditions
Neoplasms
7
Carcinoma, Non-Small-Cell Lung
6
Heart Diseases
3
Vascular Diseases
2
Small Cell Lung Carcinoma
2
Leukemia, Myeloid, Acute
2
Cardiovascular Diseases
2
Cardiotoxicity
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Cancer Resectable
1
Ovarian Carcinosarcoma
1
Noonan Syndrome 5
1
Neoplasms, Second Primary
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Metabolic Diseases
1
Liver Neoplasms
1
Leukemia, Monocytic, Acute
1
Leukemia, Lymphoid
1
Immune-related Adverse Event
1
Hematologic Neoplasms
1
Heart Failure
1
Esophageal Neoplasms
1
Early Hormone Receptor-positive Breast Cancer
1
Drug-Related Side Effects and Adverse Reactions
1
Colorectal Neoplasms
1
Interventions
Doxorubicin
17
Echocardiography
14
Cyclophosphamide
9
Trastuzumab
8
Exercise
8
Dexrazoxane
8
Electrocardiography
7
Razoxane
6
Carvedilol
6
Vincristine
4
Radiotherapy
4
Filgrastim
4
Docetaxel
4
Methotrexate
3
Granulocyte Colony-Stimulating Factor
3
Etoposide
3
Cisplatin
3
Atorvastatin
3
salicylhydroxamic acid
2
sacubitril and valsartan sodium hydrate drug combination
2
empagliflozin
2
dapagliflozin
2
Tablets
2
Social Determinants of Health
2
Silymarin
2
Prednisone
2
Paclitaxel
2
Neoadjuvant Therapy
2
Magnetic Resonance Spectroscopy
2
Leucovorin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Cardiotoxicity
×
Antineoplastic Agents
×
Clear all
NCT03882580
2023-04-24
NEOCARDIO
Groupe Hospitalier Pitie-Salpetriere
Unknown
5,000 enrolled
NCT03530215
2023-04-13
EROCA
Groupe Hospitalier Pitie-Salpetriere
Completed
500,000 enrolled